首页>
外国专利>
A METHODOLOGY FOR SELECTING SUPERAGONISTS, ANTAGONISTS AND SUPERANTAGONISTS OF HUMAN INTERLEUKIN-6 BASED ON RECEPTOR COMPLEX THREE DIMENSIONAL MODELLING
A METHODOLOGY FOR SELECTING SUPERAGONISTS, ANTAGONISTS AND SUPERANTAGONISTS OF HUMAN INTERLEUKIN-6 BASED ON RECEPTOR COMPLEX THREE DIMENSIONAL MODELLING
展开▼
机译:基于受体复杂三维模型的人类白细胞介素6的超级激动剂,拮抗剂和超激动剂选择方法
展开▼
页面导航
摘要
著录项
相似文献
摘要
It is known that the ligands of the group of cytokincs similar to Interleukin 6 (IL-6), that is Oncostatin M (OSM), Leukemia Inhibitory Factor (LIF), Ciliary Neurotrophic Factor (CNTF) and Interleukin 11 (IL-11) , induce the formation of a receptor complex of which the membrane molecule gp 130 is a part. The present invention refers to a methodology for selecting superagonists, antagonists and superantagonists of human interleukin-6 comprising the following operations: - comparing the amino acid sequence of bovine granulocyte colony stimulating factor (bG-CSF) with the sequence of said hormone; and - on the basis of the above comparison, formulating a three dimensional model of said hormone, which allows the identification of residues that form the site of interaction with the specific receptor (Site 1) and those that constitute the site of interaction with gp 130 (Site 2) respectively. The invention allows the identification of these sites in human interleukin-6 and the isolation of variants having, with respect to the wild type hormone, a greater affinity for the specific receptor (superagonists and superantagonists) or affinity for gp 130 reduced or abolished (antagonists and superantagonists). The figure shows a scheme illustrating the methodology applied to identify site 1 and site 2 in the case of human interleukin-6. The invention also describes the obtaining of specific superagonists and superantagonists of interleukin-6 and the use of superantagonists as low dose inhibitors of the growth of human myeloma cells dependent on wild type interleukin-6. (Figure 1)
展开▼